Performance of Pulmonary Embolism Risk Scores Out Come in CTPA Confirmed Patients

November 7, 2022 updated by: Nourhan Safwat Abdelraheem Hussien, Assiut University

Performance of Pulmonary Embolism Risk Scores for Assessment of Outcome in Computed Tomographic Pulmonary Angiography Confirmed Patients

  1. Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients.
  2. Compare PERFORM score with the currently validated PESI in risk stratification of patients

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Pulmonary embolism (PE) is a common and potentially lethal condition in the emergency department requiring early and accurate management.

The short-term mortality rate of PE varies widely and ranges from less than 2% in many patients with non massive PE to more than 95% in patients who experience cardiorespiratory arrest.

Although several prognostic models of acute PE are currently used, all of them have practical limitations.

Of all clinical scores integrating PE severity and comorbidity, the Pulmonary Embolism Severity Index (PESI) and its simplified version,(sPESI) have been most extensively validated to date.

However, current prognostic scores for pulmonary embolism (PE) are partly based on patients without PE confirmation via computed tomographic pulmonary angiography (CTPA), involving subjective parameters and complicated scoring methods [8].

Therefore, an objective, accurate, and simple prognostic model in CTPA-confirmed patients to predict the risk of 30-day mortality. help clinicians assess patients' risks and improve therapeutic decision-making that is called PERFORM score (pulmonary embolism risk score for mortality)

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study will be on patients wh are above 18 years okd who are daignosed to have pulmonary embolism with CTPA

Description

Inclusion Criteria:

- Patients above 18 years old with PE confirmed by CTPA are considered for inclusion in the study.

Exclusion Criteria:

  • • Patients who have contraindications for CTPA eg. Renal impairment

    • Patients diagnosed and treated as PE without doing CTPA.
    • Patients who refuse to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients.
Time Frame: from 11/2022 to 4/2024
from 11/2022 to 4/2024

Secondary Outcome Measures

Outcome Measure
Time Frame
Compare PERFORM score with the currently validated PESI in risk stratification of patients.
Time Frame: from 11/2022 to 4/2024
from 11/2022 to 4/2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

November 1, 2022

Primary Completion (Anticipated)

April 1, 2024

Study Completion (Anticipated)

April 1, 2024

Study Registration Dates

First Submitted

November 7, 2022

First Submitted That Met QC Criteria

November 7, 2022

First Posted (Actual)

November 14, 2022

Study Record Updates

Last Update Posted (Actual)

November 14, 2022

Last Update Submitted That Met QC Criteria

November 7, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • performance score outcome

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe